• Molecular NameDarunavir
  • SynonymAIDS073035; Darunavirum [INN-latin]; TMC-114; TMC114; UIC-94017
  • Weight547.673
  • Drugbank_IDDB01264
  • ACS_NO206361-99-1
  • Show 3D model
  • LogP (experiment)2.15
  • LogP (predicted, AB/LogP v2.0)2.5
  • pkaN/A
  • LogD (pH=7, predicted)2.5
  • Solubility (experiment)0.15 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-5.61
  • LogSw (predicted, AB/LogsW2.0)0.02
  • Sw (mg/ml) (predicted, ACD/Labs)0.0
  • No.of HBond Donors4
  • No.of HBond Acceptors10
  • No.of Rotatable Bonds12
  • TPSA148.8
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA drug used to treat HIV infection. It is in the protease inhibitor class.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability37.0
  • Protein binding95.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmDarunavir is extensively metabolized by CYP enzymes, primarily by CYP3A.
  • Half life15 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityThe most common treatment-emergent adverse events (> 10%) reported in the de novo subjects, regardless of causality or frequency, were diarrhea, nausea, headache, and nasopharyngitis.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A